Meet the management and board of the 21st century brewers.
Neil GoldsmithCEO and Co-founderView Bio
CEO and Co-founder
Neil co-founded Evolva in 2004. He has been a member of the Board of Directors and CEO of Evolva SA since its foundation and of Evolva Holding SA since 2009. Neil has a 27-year entrepreneurial track record in building successful biotech companies. He was a co-founder of Topotarget A/S (listed in Copenhagen, merged with BioAlliance Pharma in 2014 to become Onxeo) and Personal Chemistry AB (now called Biotage AB, listed on the Stockholm exchange). Prior to that, he was Chief Executive Officer of Auda Pharmaceuticals (acquired by Phytera, Inc.), GX Biosystems and PNA Diagnostics (acquired by Boehringer Mannheim). Previously, he was Vice-President Business Development for Pharmacia Biosensor (later BIAcore AB) and a Board member of Quadrant Healthcare. He started his career in biotech at Scientific Generics in Cambridge, UK, after a short spell in consumer marketing. From 1981 to 1984, he attended Balliol College, University of Oxford, receiving a first class honours degree in Zoology, and is a graduate of the New Enterprise programme at the Scottish Enterprise Foundation, University of Stirling. Neil is on the board of the Biotechnology Industry Organization (“BIO”) and its section “Industrial and Environmental”.
Jakob Dynnes HansenChief Financial OfficerView Bio
Jakob Dynnes Hansen
Chief Financial Officer
Jakob has been the Chief Financial Officer of Evolva since September 2007. He has 25 years of experience in biotech/pharmaceuticals and financing. Prior to joining Evolva, he was CFO of Nuevolution A/S and before that Zealand Pharma A/S, where he led several financing rounds and major partnership agreements. Prior to Zealand Pharma, Jakob was Senior Vice-President, at Unibank (now Nordea), where he was involved in more than 50 corporate finance transactions. Prior to Unibank, he was Head of Market Research at Novo Nordisk and has worked for the United Nations (UNIDO) in Jakarta, Indonesia. Jakob holds an MSc in Economics from University of Copenhagen and an MBA from Insead.
Jørgen HansenChief Scientific OfficerView Bio
Chief Scientific Officer
Jørgen joined in 2005 as Head of Research at Evolva Biotech A/S, the group’s Danish unit. He moved to the Chief Scientific Officer position in May 2013. Before joining Evolva, Jørgen held research and managerial positions in the biotech company Poalis A/S and at the Carlsberg Laboratory, where he also did his Ph.D. studies. In these companies, he gathered extensive knowledge and experience in the areas of small molecule biosynthesis, enzymatic glycosylation and yeast engineering. During his career, he has published more than 20 peer reviewed scientific papers and five book chapters and reviews. In addition, he holds multiple patents and patent applications. He has a Ph.D. in Yeast Genetics from the University of Copenhagen.
Luc GrunerSales & Marketing OfficerView Bio
Sales & Marketing Officer
Luc was appointed to the new position of Chief Sales & Marketing Officer in 2014. He joined Evolva in 2010 and has a broad background in sales/marketing, strategic planning and business development. He has been instrumental in acquiring and managing several of our partnering projects. During his career he has held senior sales and management positions in both biotechnology and specialty chemicals companies (including Bim Kemi, Hercules & WR Grace). Luc has a PhD in Physical Chemistry and an MBA from INSEAD.
Panchapagesa MuraliManaging Director & CEO, Evolva IndiaView Bio
Managing Director & CEO, Evolva India
Murali has been the Chief Executive Officer of Evolva’s Indian subsidiary, since September 2006. He has over 20 years of experience in pharmaceutical & health care R&D, including management of more than ten clinical trials, in particular in respiratory diseases. Previously, he was Founder and Director (for 16 years) of Dalmia Centre for Research and Development, developing and launching natural product-based therapeutics, and Founder and Chairman of MLC & Netpeople group of IT & Telecom companies (networking solutions, banking security and communication services). He is a former Indo-US scientist at Battelle-Kettering, Ohio, and fellow of Unilever India. He received a PhD in Microbiology and Microbial Technology from Madurai Kamaraj University. Murali is the President of the Association of Biotechnology Led Enterprises in India. He is on the Board of Dalmia Research and Development Limited and a member of the Governing Board of Dalmia Centre for Research and Development. He is Vice-President and Treasurer of the Indian Red Cross Society and chairperson of the Biotech panel of the Confederation of Indian Industrys Tamil Nadu and a member of the Vision Group of the Government of Karnataka.
Simon WaddingtonChief Operating Officer (Products)View Bio
Chief Operating Officer (Products)
Simon is COO (Products) and CEO of Evolva Inc. He was previously President and CEO of Abunda which was acquired by Evolva in July 2011. He spent more than a decade as a venture capitalist. He was a managing partner at Poly-Technos Venture Partners, based in Munich, Germany, where he led and supported investments in numerous life science and advanced materials-related companies in Europe, Israel and the US. Prior to that, he started and ran Monsanto’s European corporate venturing activities from Brussels, Belgium, where he sourced and supported innovations across the medical, agricultural, nutrition, health care services and advanced materials sectors. Before that he was Product Development Manager for Zeneca’s biopolymers business, which pioneered the fermentation-based production of bio-degradable polymers from renewable feedstocks. Prior to that, he served as a Senior Research Scientist for ICI specialising in surface and interface science. Simon earned his PhD in Physics from Liverpool University and his MBA from the Harvard Business School.
Pascal LongchampChief Business OfficerView Bio
Chief Business Officer
Pascal was appointed the Company’s Chief Business Officer in 2010. Prior to that, he was Vice-President Business Development since March 2005. Pascal has spent over 15 years in the biotechnology and pharmaceutical industries, covering R&D, Management and Business Development positions on the West Coast (USA) and in Switzerland. Previously, he was the Director of Business Development at Phyllom (2003), and a part of Maxygen’s successful IPO. At Maxygen, he was in charge of two corporate alliances and promotion of its gene shuffling platform technology to third parties. At Phistem, Maxygen and Phyllom, Pascal was responsible for corporate development, strategic alliances, in- and out-licensing, leading international research collaboration and US government contract with the Department of Defense. He has a PhD in Genetics and Microbiology from the University of Lausanne, followed by postdoctoral research at UC Berkeley in Molecular Biology and at Lawrence Berkeley National Laboratory in Biodefence. He has an MBA from HEC Business School, Lausanne.
Tom McKillopBoardView Bio
Tom has been a member of the Board of Directors since June 2010 and its Chairman since May 2012. Tom was educated at Irvine Royal Academy, Glasgow University (where he took a BSc Hons and PhD in Chemistry), and Centre de mecanique ondulatoire appliquee (Paris). He had a long and successful career at ICI, where he held a number of increasingly senior R&D positions until his appointment in 1989 as Technical Director and Deputy Chairman of ICI Pharmaceuticals, a role in which he had global responsibility for research, development, medical and production. In 1994, he was appointed Chief Executive Officer of Zeneca Pharmaceuticals – Zeneca having demerged from ICI in 1993 – and, on completion of the merger of Astra and Zeneca in April 1999, he became Chief Executive of AstraZeneca plc, a position he held until retiring on 31 December 2005. He was President of the Science Council in the UK 2007-2011 and is currently a non-executive director of Alere Inc, Almirall SA, UCB SA and Theravectys SAS. During his career he has received many scholarly awards and fellowships and was knighted in 2002 for services to the pharmaceutical industry.
Claus BraestrupBoardView Bio
Claus has been a member of the Board of Directors since June 2010 and its Vice-Chairman since May 2012. He holds a Master’s degree in Chemical Engineering and an MSc in Biochemistry. He is Doctor of Medical Science and former Adjunct Professor in Neuroscience at the University of Copenhagen. He started his career in research and consultancy positions. He then moved to Novo Nordisk A/S, where he served as Vice-President of Pharmaceutical Research, President of the CNS Division and President of the Diabetes Care Division. He subsequently took the post of Head of Preclinical Drug Research at Schering AG, before joining H. Lundbeck A/S as Executive Vice-President, Research and Development. From 2003 to 2008 Claus was President and CEO of H. Lundbeck A/S. Claus is member of the Board of Bavarian Nordic A/S, Santaris Pharma A/S, Probiodrug AG (chair) Gyros AB and Aniona (chair).
Martin GertschBoardView Bio
Martin has been a member of the Board of Directors since May 2012. He is an experienced Board member and Chief Financial Officer (CFO) in the life science industry. His most recent position was CFO of Acino Pharma AG, from which he stepped down in January 2014 after the acquisition by two private equity firms Avista Capital and Nordic Capital. He is former Vice-President Head of Finance EMEA at DePuySynthes and former Chief Financial and Chief Operating Officer of Delenex Therapeutics and ESBATech, two privately held biotech companies. From 2002 to the beginning of 2006, he was Chief Financial Officer of Straumann, which he had joined in 1997 as head of group controlling and reporting. Between 1986 and 1997, Martin was an audit engagement manager at PricewaterhouseCoopers, Basel, Switzerland. He is a Swiss certified fiduciary and Swiss certified public accountant. He has also completed several executive-level development programmes at IMD (International Institute for Management Development) in Lausanne, Switzerland. Martin is Chairman of the Board of Santhera Pharmaceuticals and Board Member of the University Center of Dentistry, Basel (UZB).
Neil GoldsmithBoardView Bio
Neil co-founded Evolva in 2004. He has been a member of the Board of Directors and CEO of Evolva SA since its foundation and of Evolva Holding SA since 2009. He has a 27-year entrepreneurial track record in building successful biotech companies. He was a co-founder of Topotarget A/S (listed in Copenhagen, merged with BioAlliance Pharma in 2014 to become Onxeo) and Personal Chemistry AB (now called Biotage AB, listed on the Stockholm exchange). Prior to that, Neil was Chief Executive Officer of Auda Pharmaceuticals (acquired by Phytera, Inc.), GX Biosystems and PNA Diagnostics (acquired by Boehringer Mannheim). Previously, he was Vice-President Business Development for Pharmacia Biosensor (later BIAcore AB) and a Board member of Quadrant Healthcare. Neil started his career in biotech at Scientific Generics in Cambridge, UK, after a short spell in consumer marketing. From 1981 to 1984, he attended Balliol College, University of Oxford, receiving a first class honours degree in Zoology, and is a graduate of the New Enterprise programme at the Scottish Enterprise Foundation, University of Stirling. He is on the board of the Biotechnology Industry Organization (“BIO”) and its section “Industrial and Environmental”.
Jutta HeimBoardView Bio
Jutta worked for more than 20 years at Ciba-Geigy/Novartis (CH and US). At Novartis, she was involved in the successful development and launch of anti-thrombotic and fibrinolytic products. She established Novartis’ molecular genetics department in oncology, became Novartis’ Senior Scientific Expert in Molecular Biology and a member of the Research Management Board. She completed her career at Novartis heading the Novartis Lead Discovery Center with worldwide responsibility. From 2004 to 2009, Jutta served as CSO at Basilea Pharmaceutica Ltd., a Swiss biopharmaceutical company focusing on anti-infectives, inflammation and oncology. From 2009 to 2013, she served as CTO and CSO at Evolva. She received a PhD from the University of Tübingen in 1981 and holds a professorship in Biotechnology at the Biocenter of the University of Basel. Jutta is a member of the advisory board of ‘‘Stiftung für Wissenschaftliche Forschung Universität Zürich’’ and serves on the board of Nuevolution A/S.
Ganesh KishoreBoardView Bio
Kish has been a member of the Board of Directors since May 2011. He received his PhD in biochemistry from the Indian Institute of Science after which he pursued postdoctoral research in chemistry and biology at the University of Texas at Austin. In 1980, he joined Monsanto where he held senior positions in the areas of biotechnology and in the Nutrition and Consumer Products division. During his tenure at Monsanto he was involved in the development of major products such as Aspartame (the active ingredient of several major sweetener products) as well as a key agricultural crop protection technology. Kish joined DuPont in 2002 as the Chief Technology Officer for its Agriculture and Nutrition Platform and took over the role of Chief Biotechnology Officer for the company in 2005. He is currently CEO of MLSCF (Malaysian Life Sciences Capital Fund), which is a shareholder in Evolva. His other Board mandates include Advanta, Kaiima, Gevo, Glori Energy, Sentinext, Mogene and Akermin. He is on the board of several academic institutions.
Stuart StrathdeeBoardView Bio
Stuart has been a member of the Board since May 2011. Having completed his PhD in Applied Physics, he joined Tate & Lyle plc in 1977 as a management trainee. He retired from the company in July 2009, having served on the main Board as an Executive Director in various roles for 14 years. During his time at Tate & Lyle, Stuart held a variety of senior management positions including Group Treasurer, Managing Director of both United Molasses and Tate & Lyle’s International Division and was Corporate Development Director reporting to the Chief Executive Officer from July 2003. Leadership highlights include: the development of Tate & Lyle’s sucralose ingredient business; creation of Vietnam’s leading sugar business; the public takeover of Australia’s largest sugar farming company; creation of a joint venture to construct the Middle East’s largest sugar refinery; the acquisition of publicly listed Zambia Sugar Company, now Africa’s leading sugar milling company. Stuart has a PhD in Atomic and Molecular Physics from Queens University Belfast. He is a member of the Board of James Finlay Ltd.
Thomas VidebaekBoardView Bio
Thomas has been a member of the Board of Directors since May 2012. He has been a member of the Novozymes Executive Management Group since September 2007, currently responsible for corporate business development. Thomas joined Novo Nordisk as a chemist in 1988 and worked in various positions in the Textiles and Starch divisions, both in Denmark and in the US. In 1996, he assumed responsibility for Food and Feed enzymes and was appointed Director for Strategic Marketing, Food and Feed enzymes. At the end of 1998, Thomas was appointed General Manager for Novozymes Switzerland and also Vice-President for Cereal Food and Beverage Marketing. He returned to Denmark in 2003 and became Vice-President for Supply Chain Operations where he was responsible for establishing a global organisation in charge of the supply chain at Novozymes. Thomas holds a Master of Chemical Engineering from DTU, Dept. of Nutrition and Biochemistry, Copenhagen 1986, and a PhD from DTU in 1990. He also holds a BCom (International Business) from the Copenhagen Business School (1992).
Making alliances work
Evolva believes that good collaborations require good communication, good science and engineering, and of course good results.Harvard Bus. Review
What’s going on in Copenhagen
Copenhagen is home to our second largest operation and is the heart of our fermentation R&D.Visit Copenhagen
8 Tips to Help Communicate a Controversial Topic
Today there is no shortage of advice for biotech innovators looking for outside perspectives on how to engage with the public.Composition Logic